KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Liabilities: 2012-2024

Historic Total Liabilities for Xenon Pharmaceuticals (XENE) over the last 12 years, with Dec 2024 value amounting to $43.2 million.

  • Xenon Pharmaceuticals' Total Liabilities rose 26.86% to $48.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.3 million, marking a year-over-year increase of 26.86%. This contributed to the annual value of $43.2 million for FY2024, which is 17.24% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Total Liabilities stood at $43.2 million for FY2024, which was up 17.24% from $36.9 million recorded in FY2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Total Liabilities peaked at $43.2 million during FY2024, and registered a low of $17.8 million during FY2020.
  • Over the past 3 years, Xenon Pharmaceuticals' median Total Liabilities value was $36.9 million (recorded in 2023), while the average stood at $37.6 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 68.00% in 2020, then skyrocketed by 48.58% in 2022.
  • Xenon Pharmaceuticals' Total Liabilities (Yearly) stood at $17.8 million in 2020, then rose by 23.23% to $22.0 million in 2021, then skyrocketed by 48.58% to $32.6 million in 2022, then climbed by 12.95% to $36.9 million in 2023, then climbed by 17.24% to $43.2 million in 2024.